Pharmaceutical Research and Manufacturers of America (PhRMA)
| Pharmaceutical Research and Manufacturers of America (PhRMA) | |
 | |
| Basic facts | |
| Location: | Washington, D.C. |
| Type: | 501(c)(6) |
| Top official: | Steve Ubl, President and CEO |
| Year founded: | 1958 |
| Website: | Official website |
The Pharmaceutical Research and Manufacturers of America (PhRMA) is a 501(c)(6) nonprofit organization headquartered in Washington, D.C. According to its website, they are "working to drive patient-centered progress in innovation, affordability, and access to life saving prescription medicines."[1][2]
Background
PhRMA was founded in 1958 with the intention "to represent America’s biopharmaceutical research companies and seek essential alignment between public policy and medical research to address patient needs." PhRMA has offices in the United States, China, and Japan. PhRMA members spent around $51.2 billion in 2014 developing new medicines.[3][4]
According to its website, PhRMA's mission is "to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.[4]
The full list of companies that are members can be found on its website.
 |
| Healthcare policy in the U.S. |
|---|
| Obamacare overview |
| Obamacare lawsuits |
| Medicare and Medicaid |
| Healthcare statistics |
|
Leadership
The following were listed as part of the company's leadership:[5]
- Albert Bourla, DVM, Ph.D, Board Chair
- Paul Hudson, Board Chair-elect
- Robert M. Davis, Treasurer
- Miguel Fernández Alcalde,
- Brad Bailey,
- Chris Boerner, Ph.D.,
- Jean-Michel Boers,
- Robert A. Bradway,
- Kyle Gano, Ph.D.,
- Thomas Gibbs,
- Sebastian Guth, Ph.D.,
- Alexander Hardy,
- Ken Keller,
- Julie Kim,
- David Loew,
- Ashley Magargee,
- Tsutomu Nakagawa, Ph.D,
- Vasant (Vas) Narasimhan, M.D.,
- Daniel O'Day,
- Michael Petroutsas,
- Richard F. Pops
- Tarek Rabah
- David Ricks
- Steve Schaefer,
- Pascal Soriot,
- Jennifer Taubert,
- Jean-Christophe Tellier, M.D.,
- Chris Viehbacher,
- Emma Walmsley,
- Tatsuyuki Yasuno,
- Stephen J. Ubl,
- Lori M. Reilly, Esq.,
- Robert Zirkelbach,
- Elizabeth Carpenter,
- Lucy Vereshchagina, Ph.D.,
- James C. Stansel,
- Tracey Merchant,
- Renuka Iyer,
Work and activities
According to its website, PhRMA says it wants to do the following:[3]
| “ | Adopt a pro-innovation regulatory and trade agenda
Preserve the uniquely American system that balances incentives for innovation with affordability by protecting intellectual property at home and abroad, modernizing the FDA to keep pace with innovation, defending American workers and limiting foreign free-riding through strong trade agreements. Protect the United States from the harms of price setting Protect patients, pharmacists and providers from the harms of price setting policies that undermine innovation and create new access barriers for American patients. Fix the IRA’s pill penalty to allow all medicines to compete for 13 years before eligibility for government price setting and prevent further expansion of price setting to maintain patient choice of medicines. Stop the abuse in the 340B hospital markup program Pursue comprehensive reform that prevents abuse and ensures the 340B program lowers medicine costs for low-income patients. Do not stand in the way of private market solutions that would ensure program compliance and limit illegal activity. Rein in the middlemen to put patients over PBM profits Stop PBM practices that are driving up costs and limiting access for patients by sharing savings negotiated between manufacturers and PBMs directly to patients, delinking PBM compensation from the list price of medicine, ensuring patients benefit from manufacturer assistance programs and holding health plans accountable for providing patient care.[6] |
” |
Policy advocacy
PhRMA's website lists policy issues that they focus on, including the following:[7]
- Intellectual Property
- Research & Development
- Innovative Medicines
- Government Price Setting
- International
- PBMs and Middlemen
- Hospitals and 340B
- Insurance Coverage
- Cost of Medicines
- Medicare and Medicaid
Ballot measure activity
The following table details PhRMA's ballot measure stances available on Ballotpedia:
| Ballot measure support and opposition for PhRMA | ||||
|---|---|---|---|---|
| Ballot measure | Year | Position | Amount | Status |
| California Proposition 41, Veterans Housing and Homeless Prevention Bond (June 2014) | 2014 | Supported | $10,000[8] | 
|
| California Proposition 93, Amendment to Term Limits Initiative (February 2008) | 2008 | Supported | $500,000[9] | 
|
| California Proposition 89, Public Campaign Finance Program, Campaign Finance Limits, and Increased Corporate Tax Initiative (2006) | 2006 | Opposed | $200,000[10] |
|
| Florida Amendment 3, Supermajority Vote Required to Approve a Constitutional Amendment (2006) | 2006 | Supported | $100,000[11] |
|
| California Proposition 79, Prescription Drug Discount Program Initiative (2005) | 2005 | Opposed | $80,394,902[12] |
|
| California Proposition 78, Prescription Drug Discount Program Initiative (2005) | 2005 | Supported | $85,998,683[13] |
|
Finances
The following is a breakdown of PhRMA's revenues and expenses from XXXX to XXXX. The information comes from the Internal Revenue Service
| Year | Revenue | Expenses |
|---|---|---|
| 2015 | $4.2 million | $4.4 million |
| 2016 | $4.3 million | $3.6 million |
| 2017 | $4.7 million | $4.0 million |
| 2018 | $5.2 million | $4.1 million |
| 2019 | $4.8 million | $5.2 million |
| 2020 | $5.1 million | $4.8 million |
| 2021 | $3.7 million | $4.4 million |
| 2022 | $3.9 million | $4.1 million |
Recent news
The link below is to the most recent stories in a Google news search for the terms 'PhRMA'. These results are automatically generated from Google. Ballotpedia does not curate or endorse these articles.
See also
External links
- Pharmaceutical Research and Manufacturers of America
- PhRMA on Twitter
- PhRMA on Facebook
- PhRMA on YouTube
- PhRMA on Flickr
Footnotes
- ↑ ProPublica, "Pharmaceutical Research And Manufacturers Of America." accessed October 30, 2025
- ↑ PhRMA, "Homepage," accessed October 30, 2025
- ↑ 3.0 3.1 PhRMA, "About PhRMA," accessed October 30, 2025
- ↑ 4.0 4.1 PhRMA, "Our Agenda," accessed October 30, 2025
- ↑ PhRMA, "At the Forefront of Change," accessed October 31, 2025
- ↑ Note: This text is quoted verbatim from the original source. Any inconsistencies are attributable to the original source.
- ↑ PhRMA, "Policy Issues," accessed October 31, 2025
- ↑ Follow the Money, "PROPOSITION 041 (PRIMARY), Top Supporting Donors," accessed August 23, 2016
- ↑ Follow the Money, "PROPOSITION 093, Top Supporting Donors," accessed August 23, 2016
- ↑ Follow the Money, "PROPOSITION 089, Top Opposing Donors," accessed August 23, 2016
- ↑ Follow the Money, "PROTECT OUR CONSTITUTION, Top Donors," accessed August 23, 2016
- ↑ Follow the Money, "Campaign spending on Proposition 79," accessed August 23, 2016
- ↑ Follow the Money, "Campaign spending on Proposition 78," accessed August 23, 2016
| |||||||
